HONG KONG, December 31, 2021 / PRNewswire / – Great Bay Bio (GBB), an AI-powered biotech company, announces FutureX Capital’s participation in its Series A fundraiser.
Great Bay Bio completed A fundraising round of nearly 10 USD million to December 1, 2021. Investors understand Promixa Ventures, GL Ventures, Alibaba Entrepreneurs Fund, Alon Capital and FutureX Capital.
“Thank you for the compelling support from FutureX Capital. We look forward to working with FutureX to enrich Great Bay Bio’s entrepreneurial ecosystem and accelerate the pace of the application of cutting-edge technologies such as artificial intelligence in development platforms. of drugs, “said Kingsley leung, co-founder and president of GBB.
Zhang Hanqin, Partner of FutureX Capital, comments: “FutureX Capital continues to focus on the innovative application of AI technology in scientific research. Based on his deep understanding of industry weak points and his wealth of experience in the field of biologics. research and development, Great Bay Bio (GBB) has successfully applied AI technology to the entire process of cell line culture and screening, dramatically shortening R&D time, reducing the cost of trial and error. R&D and boosting the promising biopharmaceutical industry at a high speed level, ultimately benefiting every ordinary person. Together with the founding team and our shareholders, we look forward to exploring the possibilities of AI-powered pharmaceutical R&D and its application in a wider range of fields. “
About Great Bay Bio
Great Bay Bio (GBB) is a Hong KongHigh-tech company based on the application of artificial intelligence and other cutting-edge technologies in CMC bioprocessing, ultimately solving many pain points in the biopharmaceutical industry, including high failure rates, a long development time and high costs. Since its inception, the company has accumulated enormous bioprocess development data from its 3,100 m2 CMC facility, which reinforces advanced equipment from world-renowned manufacturers. GBB has also succeeded in bringing a number of biologics to the NDA stage, some of which are classified as national class I innovative drugs. Currently, the company has created an intelligent centralized database, where deep learning is carried out to create a next-generation bioprocessing ecosystem encompassing AI.
GBB has twice been awarded the titles of “National High-Tech Enterprise” by the National High-Tech Enterprise Certification Management Steering Group Office, “Sprouts List Most Valuable Enterprises for Investment in China for the Year 2020 “by the Zero2IPO group,” Top 50 Innovative Biotechnology Companies in Guangdong-Hong Kong-Macao Greater Bay Area Award 2020 ”by ZDVC RESEARCH and KPMG China, and ranked in the top 15 at the Merck Greater Bay Area Innovation Bootcamp 2021.
FutureX Capital is a mid-to-late stage private equity investment platform that focuses on exploring the growth opportunities of the smart age and high-tech industries. It is committed to exploring the smart era investment configuration and seeking the transformation of the investment industry. The main areas of investment include artificial intelligence, cloud computing, Internet of things, chip semiconductors, 5G, computers, ICT +, etc.
E-mail: [email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/gbb-closed-the-a-round-financing-with-newly-joined-futurex-capital-301452316.html
SOURCE Grande Baie Bio